Search Results | MSF Science Portal

Journal Article

|

Commentary

Guglielmetti L, Panda S, Abubakirov A, Salahuddin N, Perrin C, et al.

2025-03-21 • Lancet Respiratory Medicine

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2024-02-01 • Lancet Respiratory Medicine

BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Journal Article

|

Research

Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, et al.

2017-03-15 • Lancet Respiratory Medicine

Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tube...

Journal Article

|

Commentary

Keene CM, Mohr-Holland E, Cassidy T, Scott V, Nelson AM, et al.

2020-09-01 • Lancet Respiratory Medicine

Journal Article

|

Research

Schnippel K, Ndjeka N, Maartens G, Meintjes GA, Master I, et al.

2018-09-01 • Lancet Respiratory Medicine

Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Foll...

Journal Article

|

Commentary

Apolisi I, Mema N, Tyeku N, Beko B, Memani B, et al.

2022-03-01 • Lancet Respiratory Medicine

Journal Article

|

Research

Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, et al.

2020-03-17 • Lancet Respiratory Medicine

BACKGROUND

Tre...

Journal Article

|

Commentary

Hughes J, Snyman L

2018-02-05 • Lancet Respiratory Medicine

Journal Article

|

Commentary

Reuter A, Furin J

2018-09-01 • Lancet Respiratory Medicine

Journal Article

|

Commentary

KumarAMV, Gupta D, Gupta RS, Satyanarayana S, Wilson N, et al.

2012-10-24 • Lancet Respiratory Medicine

Science Portal

Equitable, personalised medicine for tuberculosis: Treating patients, not diseases

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

The Epidemiology, Pathogenesis, Transmission, Diagnosis, and Management of Multidrug-Resistant, Extensively Drug-Resistant, and Incurable Tuberculosis

How COVID-19 could benefit tuberculosis and HIV services in South Africa

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

Supporting families with tuberculosis during COVID-19 in Khayelithsa, South Africa

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis

Palliative care for drug-resistant tuberculosis: when new drugs are not enough

Bedaquiline use in South Africa reveals a lifesaving policy in action

HIV testing in people with presumptive tuberculosis: time for implementation